Sham radiation in clinical trials assessing radiotherapy for exudative age-related macular degeneration.
BACKGROUND
To evaluate the effectiveness of sham radiation treatments in masking patients to their randomization group in the Radiation of Age-Related Macular Degeneration (ROARMD) Study.


METHODS
Patients with choroidal neovascularization complicating age-related macular degeneration were randomized to a treatment (RAD) group that received external beam irradiation (seven treatment sessions) or to a control (SHAM) group that received sham radiation (one sham treatment session). During a telephone survey, 62 of 73 randomized patients responded to the following questions: Do you think you received radiation? Why do you feel that way? Did the vision in your study eye worsen after enrollment?


RESULTS
Eighty-one percent of the RAD group and 59% of the SHAM group thought that they had received radiation. In patients who thought that their vision had stabilized or improved, 82% thought that they had received radiation. In patients who thought that their vision was worse, only 39% thought that they had received radiation. In 54% of patients, subjective perception of vision influenced their guess as to whether they received radiation.


CONCLUSIONS
Subjective patient perception of visual outcome was the most influential variable for masking. Variation between radiation treatment and sham session techniques, such as equipment used and duration of treatments, played a lesser role in the masking of patients. Seven treatment days correlated with a higher number of patients who thought that they had received radiation. Although our procedures do not strictly mask the two groups, one sham radiation session was effective in keeping patients guessing their randomization group.
Marcus
D M
DM
Department of Ophthalmology, Medical College of Georgia, Augusta 30912, USA.
Camp
M W
MW
Sheils
W C
WC
McIntosh
S B
SB
Leibach
D B
DB
Johnson
M H
MH
Samy
C N
CN
D000368:Aged; D000369:Aged, 80 and over; D020256:Choroidal Neovascularization / Q000209:etiology / Q000532:radiotherapy*; D018450:Disease Progression; D004311:Double-Blind Method; D005122:Exudates and Transudates; D005260:Female; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014792:Visual Acuity